Lexaria Bioscience Faces Nasdaq Delisting, Files Appeal After Reverse Split
LEXX sits 30% above its 52-week low of $4.21.
Summary
Lexaria Bioscience received a Nasdaq delisting notice after failing to meet the $1.00 minimum bid price, but has appealed and expects to regain compliance following its recent reverse stock split.
Key Events · Legal and Risk Events · LEXX
-
Nasdaq Delisting Notice Received
On August 4, 2026, Lexaria received a Nasdaq delisting notice for failing to maintain a $1.00 minimum bid price within the 180-day compliance period.
-
Reverse Split Completed Day Before
The company completed a 1-for-15 reverse stock split on August 3, 2026, which has since pushed the stock price above $1.00.
-
Hearing Request Filed to Stay Delisting
Lexaria has filed a hearing request and paid the required fee, which stays the delisting pending the appeal.
-
Going Concern and Cash Runway Pressure
The company's last 10-Q disclosed a going concern warning and cash runway only into early 2027, making Nasdaq listing critical for capital access.
Analysis · LEXX · Life Sciences
A Nasdaq delisting notice landed on Lexaria Bioscience on August 4, 2026, after the company failed to meet the $1.00 minimum bid price within the 180-day compliance window. Just one day earlier, on August 3, 2026, it completed a 1-for-15 reverse stock split, and the stock has since traded above $1.00. To stay the delisting, the company has filed a hearing request and expects to regain compliance before any hearing takes place. This is a critical survival event for a firm already operating under a going-concern warning and with a cash runway that extends only into early 2027. The reverse split was a last-ditch effort to maintain its Nasdaq listing, and the delisting notice confirms how close the company came to losing its exchange. While the appeal buys time, the risk of delisting persists if the stock price cannot sustain above $1.00.
At the time of this filing, LEXX was trading at $5.49 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $9.1M. The 52-week trading range was $4.21 to $23.25. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.